Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 3 clients • 12 examiners • 9 art units • 0 of 12 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Clark+Elbing LLP - Genentech and Roche handles Biotechnology & Pharmaceuticals matters and has 12 pending office actions. The profile records 9010 career applications, placing the current unresolved activity within a broad application history.
The resolved allowance rate is 67.77%, and the average office actions per allowance is 3.89. The figures describe historical allowance results and the examination activity associated with allowed matters. Practitioners can use this context for resource planning, while evaluating the specific scientific disclosure and claim strategy independently.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (17%) |
| §112 only | 4 (33%) |
| Double-patenting + other | 3 (25%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| HOFFMAN, ALEXANDER JOSEPH | 1 | 0.0% | +0.0% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18496065 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER | GODDARD, LAURA B | — |
| 18486325 | IN VITRO CELL-BASED ASSAY FOR PREDICTING PHARMACOKINETICS AND BRAIN PENETRATION OF BIOLOGICS | HOFFMAN, ALEXANDER JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | SITTON, JEHANNE SOUAYA | 52d overdue |
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | HALVORSON, MARK | — |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | KIM, YUNSOO | — |
| 18496065 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER | GODDARD, LAURA B | — |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | CUNNINGCHEN, KATHLEEN MARY | — |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | NOAKES, SUZANNE MARIE | — |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | SAOUD, CHRISTINE J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| GENENTECH, INC. | 8 |
| Roche | 3 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 1 |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1647 | 2 |
| 1641 | 1 |
| 1642 | 1 |
| 1677 | 1 |
| 1682 | 1 |
| 1656 | 1 |
| 1645 | 1 |
| 1643 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | Genentech, Inc. | HALVORSON, MARK | 1646 | §103Other | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | Genentech, Inc. | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | Genentech, Inc. | KIM, YUNSOO | 1641 | §103DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18496065 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER | Icahn School Of Medicine AT Mount Sinai | GODDARD, LAURA B | 1642 | §103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18486325 | IN VITRO CELL-BASED ASSAY FOR PREDICTING PHARMACOKINETICS AND BRAIN PENETRATION OF BIOLOGICS | Genentech, Inc. | HOFFMAN, ALEXANDER JOSEPH | 1677 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | Genentech, Inc. | SITTON, JEHANNE SOUAYA | 1682 | §103 | Final Rejection | 52d overdue | Pending | Jun 06, 2023 |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Genentech, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | Genentech, Inc. | NOAKES, SUZANNE MARIE | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | Hoffmann-La Roche, Inc. | SAOUD, CHRISTINE J | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | Hoffmann-La Roche, Inc. | DEBERRY, REGINA M | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | Genentech, Inc. | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d overdue | Pending | Apr 04, 2023 |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Hoffmann-La Roche, Inc. | CHATTIN, AMY MARIE | 1643 | §112Other | Non-Final OA | 26d | Pending | Dec 15, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial67.8% of resolved applications prosecuted by Clark+Elbing LLP - Genentech And Roche were allowed, across 9,010 applications in USPTO records.
3.89 office actions per allowed application on average.
12 pending office actions as of October 2026, for 3 clients, before 12 examiners in 9 art units.
